Your browser doesn't support javascript.
loading
The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population.
Alenezi, Wejdan M; Milano, Larissa; Fierheller, Caitlin T; Serruya, Corinne; Revil, Timothée; Oros, Kathleen K; Behl, Supriya; Arcand, Suzanna L; Nayar, Porangana; Spiegelman, Dan; Gravel, Simon; Mes-Masson, Anne-Marie; Provencher, Diane; Foulkes, William D; El Haffaf, Zaki; Rouleau, Guy; Bouchard, Luigi; Greenwood, Celia M T; Masson, Jean-Yves; Ragoussis, Jiannis; Tonin, Patricia N.
Afiliación
  • Alenezi WM; Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada.
  • Milano L; Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC H4A3J1, Canada.
  • Fierheller CT; Department of Medical Laboratory Technology, Taibah University, Medina 42353, Saudi Arabia.
  • Serruya C; Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University, Quebec City, QC G1V0A6, Canada.
  • Revil T; Genome Stability Laboratory, Centre de Recherche du Centre Hospitalier de l'Université de Québec, HDQ Pavilion, Oncology Axis, Quebec City, QC G1R2J6, Canada.
  • Oros KK; Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada.
  • Behl S; Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC H4A3J1, Canada.
  • Arcand SL; Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC H4A3J1, Canada.
  • Nayar P; Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada.
  • Spiegelman D; McGill Genome Centre, McGill University, Montreal, QC H3A0G1, Canada.
  • Gravel S; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC H3T1E2, Canada.
  • Mes-Masson AM; Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada.
  • Provencher D; Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC H4A3J1, Canada.
  • Foulkes WD; Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC H4A3J1, Canada.
  • El Haffaf Z; Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC H4A3J1, Canada.
  • Rouleau G; Institute of Parasitology, McGill University, Montreal, QC H9X3V9, Canada.
  • Bouchard L; Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada.
  • Greenwood CMT; Montreal Neurological Institute, McGill University, Montreal, QC H3A2B4, Canada.
  • Masson JY; Department of Human Genetics, McGill University, Montreal, QC H3A0C7, Canada.
  • Ragoussis J; McGill Genome Centre, McGill University, Montreal, QC H3A0G1, Canada.
  • Tonin PN; Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC H2X0A9, Canada.
Cancers (Basel) ; 14(9)2022 Apr 30.
Article en En | MEDLINE | ID: mdl-35565380
ABSTRACT
To identify candidate variants in RAD51C and RAD51D ovarian cancer (OC) predisposing genes by investigating French Canadians (FC) exhibiting unique genetic architecture. Candidates were identified by whole exome sequencing analysis of 17 OC families and 53 early-onset OC cases. Carrier frequencies were determined by the genetic analysis of 100 OC or HBOC families, 438 sporadic OC cases and 1025 controls. Variants of unknown function were assayed for their biological impact and/or cellular sensitivity to olaparib. RAD51C c.414G>C;p.Leu138Phe and c.705G>T;p.Lys235Asn and RAD51D c.137C>G;p.Ser46Cys, c.620C>T;p.Ser207Leu and c.694C>T;p.Arg232Ter were identified in 17.6% of families and 11.3% of early-onset cases. The highest carrier frequency was observed in OC families (1/44, 2.3%) and sporadic cases (15/438, 3.4%) harbouring RAD51D c.620C>T versus controls (1/1025, 0.1%). Carriers of c.620C>T (n = 7), c.705G>T (n = 2) and c.137C>G (n = 1) were identified in another 538 FC OC cases. RAD51C c.705G>T affected splicing by skipping exon four, while RAD51D p.Ser46Cys affected protein stability and conferred olaparib sensitivity. Genetic and functional assays implicate RAD51C c.705G>T and RAD51D c.137C>G as likely pathogenic variants in OC. The high carrier frequency of RAD51D c.620C>T in FC OC cases validates previous findings. Our findings further support the role of RAD51C and RAD51D in hereditary OC.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Canadá
...